|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of marketable securities premium | |||||
| Stock-based compensation | |||||
| Provision for credit losses | |||||
| Loss on sale of equity investment | |||||
| Loss on disposal of equipment | |||||
| Return of equity method investments as dividends | |||||
| Equity in income of unconsolidated joint ventures | |||||
| Deferred tax assets | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued liabilities | |||||
| Other long-term liabilities | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property, plant and equipment | |||||
| Proceeds from sales and maturities of available-for-sale debt securities | |||||
| Proceeds from sales of equity securities - 15% Jia Mei | |||||
| Investments in non-marketable equity investments | |||||
| Net cash used in investing activities | |||||
| Proceeds from common stock options exercised | |||||
| Cash flows from financing activities: | |||||
| Proceeds from issuance of common stock and options exercised, net of issuance costs | |||||
| Proceeds from short-term bank loans | |||||
| Payments on short-term bank loans | |||||
| Proceeds from capital increase in subsidiary shares from noncontrolling interests | |||||
| Proceeds from long-term loan | |||||
| Payments on long-term loan | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rate changes on cash, restricted cash and cash equivalents | |||||
| Net increase (decrease) in cash, restricted cash and cash equivalents | |||||
| Cash, restricted cash and cash equivalents at the beginning of the year | |||||
| Cash, restricted cash and cash equivalents at the end of the period | |||||
| Effect of exchange rate changes on cash, restricted cash and cash equivalents | |||||
| Supplemental disclosures: | |||||
| Income taxes paid, net of refunds | |||||
| Interest expense paid | |||||
| Supplemental disclosure of non-cash flow information: | |||||
| Loan proceeds received by notes receivable | |||||
| Notes receivables paid to purchase fixed assets | |||||
| Non-cash consideration received from sale of DongFang | |||||
| Investment in subsidiary shares from noncontrolling interest | |||||
| Consideration payable in connection with construction in progress, included in accrued liabilities | |||||
Loading...